Sonidegib phosphate: new approval for basal cell carcinoma
| Autor: | R. Tibes |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
medicine.medical_specialty
Skin Neoplasms Pyridines Sonidegib Receptors G-Protein-Coupled 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Cell surface receptor Internal medicine medicine Humans Drug Interactions Hedgehog Proteins Pharmacology (medical) Basal cell carcinoma SONIDEGIB PHOSPHATE Pharmacology Clinical Trials as Topic business.industry Biphenyl Compounds Cancer General Medicine medicine.disease Smoothened Receptor Hedgehog signaling pathway Endocrinology chemistry Carcinoma Basal Cell 030220 oncology & carcinogenesis Cancer research Smoothened business 030217 neurology & neurosurgery Signal Transduction |
| Zdroj: | Drugs of Today. 52:295 |
| ISSN: | 1699-4019 |
| DOI: | 10.1358/dot.2016.52.5.2470697 |
| Popis: | Basal cell carcinoma (BCC), although mostly locally confined, is the most common cancer. Most BCCs harbor inactivating mutations in the membrane receptor/gene Ptch, thereby activating the Hedgehog signaling pathway (Hh) via the essential signaling molecule Smoothened (SMO). Novel small-molecule inhibitors or antagonists of SMO have shown excellent response rates in patients with locally advanced, unresectable and metastatic BCC in roughly 35-60% of patients, with disease control rates and clinical benefit being even higher. Sonidegib is the second-in-class SMO inhibitor approved for locally advanced, unresectable and metastatic BCC. Sonidegib is given once daily continuously, with specific side effects as listed in the label indication. Resistance develops over time and knowledge gleaned from other SMO inhibitors indicates that SMO mutations preventing drug binding as well as mechanisms activating the Hh pathway downstream of SMO are responsible, ultimately reactivating Hh pathway signaling. The next challenge will be to define novel salvage and SMO combination strategies for BCC and other tumors. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|